MedicineEnvironmental Science

Estimation of Public Health Impact with Use of Nirsevimab During the 2024–2025 RSV Season in the USA: a Modeling Study

B. Yarnoff, Maureen P. Neary, Veronica Gabriel, Mehdi Ghemmouri, E. Hodges, Maribel Tribaldos, Jeroen Geurtsen, Ayman Chit, Matthieu Beuvelet, Samira Soudani, Robert Musci, L. Krilov

2026.2.26Pulmonary Therapy

DOI: 10.1007/s41030-026-00348-z

tlooto Summary

Modeled increases in coverage demonstrate large, incremental public health gains with complete universal immunization yielding up to an 86% reduction in RSV MA-LRTDs.

Abstract

Respiratory syncytial virus (RSV) is a leading cause of medically attended lower respiratory tract disease (MA-LRTD) and hospitalization among infants in the USA. With the

Citation format

YARNOFF, B., et al. Estimation of public health impact with use of nirsevimab during the 2024–2025 RSV season in the USA: A modeling study. Pulmonary Therapy, 2026, 12(2): 707–720.